- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06041386
REIMAGINE - Real World Evaluation of Mepolizumab i svær astma opnår ved behandling klinisk remission, en prospektiv undersøgelse (REIMAGINE)
En prospektiv, virkelig verden, interventionsundersøgelse til at evaluere effekten af mepolizumab på opnåelse af klinisk remission hos deltagere med svær astma
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Kortrijk, Belgien, 8500
- GSK Investigational Site
-
Liège, Belgien, 4000
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B0M3
- GSK Investigational Site
-
Calgary, Alberta, Canada
- GSK Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3L 1Z5
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1E2
- GSK Investigational Site
-
-
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- GSK Investigational Site
-
Newport Beach, California, Forenede Stater, 92663
- GSK Investigational Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 71105
- GSK Investigational Site
-
Colorado Springs, Colorado, Forenede Stater, 80923
- GSK Investigational Site
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- GSK Investigational Site
-
-
Florida
-
Homestead, Florida, Forenede Stater, 33032-8185
- GSK Investigational Site
-
Jacksonville, Florida, Forenede Stater, 32209
- GSK Investigational Site
-
Miami, Florida, Forenede Stater, 33125
- GSK Investigational Site
-
Plantation, Florida, Forenede Stater, 33317
- GSK Investigational Site
-
-
Georgia
-
Adairsville, Georgia, Forenede Stater, 30103
- GSK Investigational Site
-
Columbus, Georgia, Forenede Stater, 31904
- GSK Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40509-1801
- GSK Investigational Site
-
Owensboro, Kentucky, Forenede Stater, 42301
- GSK Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 34452
- GSK Investigational Site
-
-
Maryland
-
Glenn Dale, Maryland, Forenede Stater, 20769
- GSK Investigational Site
-
Towson, Maryland, Forenede Stater, 21204
- GSK Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48103
- GSK Investigational Site
-
-
Minnesota
-
Linwood, Minnesota, Forenede Stater, 55092
- GSK Investigational Site
-
Rochester, Minnesota, Forenede Stater, 55905-0001
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Forenede Stater, 89052-5015
- GSK Investigational Site
-
-
New York
-
Rochester, New York, Forenede Stater, 14607
- GSK Investigational Site
-
Schenectady, New York, Forenede Stater, 12308
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19140
- GSK Investigational Site
-
Philadelphia, Pennsylvania, Forenede Stater, 19141
- GSK Investigational Site
-
-
South Carolina
-
Union, South Carolina, Forenede Stater, 29379-7409
- GSK Investigational Site
-
-
Texas
-
Cypress, Texas, Forenede Stater, 77429-1439
- GSK Investigational Site
-
Kerrville, Texas, Forenede Stater, 78028
- GSK Investigational Site
-
McKinney, Texas, Forenede Stater, 75069
- GSK Investigational Site
-
-
-
-
-
Brest, Frankrig, 29200
- GSK Investigational Site
-
Cannes, Frankrig, 06614
- GSK Investigational Site
-
Lille, Frankrig, 59000
- GSK Investigational Site
-
Lyon, Frankrig, 69004
- GSK Investigational Site
-
Strasbourg, Frankrig, 67091
- GSK Investigational Site
-
Toulouse, Frankrig, 31059
- GSK Investigational Site
-
-
-
-
-
Genova, Italien, 16132
- GSK Investigational Site
-
Monserrato CA, Italien, 09042
- GSK Investigational Site
-
Naples, Italien, 80131
- GSK Investigational Site
-
Pieve Di Soligo TV, Italien, 131044
- GSK Investigational Site
-
Roma, Italien, 00128
- GSK Investigational Site
-
Roma, Italien, 161
- GSK Investigational Site
-
Rozzano, Italien, 20089
- GSK Investigational Site
-
Verona, Italien, 37126
- GSK Investigational Site
-
-
-
-
-
Gifu, Japan, 509-6134
- GSK Investigational Site
-
Kagawa, Japan, 760-0018
- GSK Investigational Site
-
Tokyo, Japan, 142-8666
- GSK Investigational Site
-
Tokyo, Japan, 173-8606
- GSK Investigational Site
-
Tokyo, Japan, 105-0003
- GSK Investigational Site
-
-
-
-
-
?Od?, Polen, 90-153
- GSK Investigational Site
-
Gdansk, Polen, 80-214
- GSK Investigational Site
-
Lodz, Polen, 92-213
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08025
- GSK Investigational Site
-
Girona, Spanien, 17005
- GSK Investigational Site
-
Valencia, Spanien, 46015
- GSK Investigational Site
-
-
-
-
-
Bonn, Tyskland, 53119
- GSK Investigational Site
-
Hohenstein-Ernsttal, Tyskland, 9337
- GSK Investigational Site
-
Schleswig, Tyskland, 53123
- GSK Investigational Site
-
-
Hesse
-
Darmstadt, Hesse, Tyskland, 64283
- GSK Investigational Site
-
Frankfurt am Main, Hesse, Tyskland, 60389
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Tyskland, 52074
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
- No NUCALA use in the 6 months prior to enrollment.
- Participants with greater than or equal to (≥)60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician.
- Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
- Written informed consent
Exclusion Criteria:
- Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
- Participants currently on maintenance OCS or intramuscular corticosteroids.
- Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment
- Participants participating in an interventional study with a treatment intervention
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Group 1
Participants with a clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care. |
Mepolizumab will be prescribed based on physician decision. Lung function via spirometry will be collected. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage (%) of Participants Achieving 4-Component Clinical Remission
Tidsramme: At month 12
|
4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function. |
At month 12
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Annualized Rates of Clinically Significant Asthma Exacerbations (CSE) and CSE Leading to Hospitalization/ Emergency Room (ER) Visits
Tidsramme: At month 12
|
CSE is defined as a deterioration in asthma requiring (1) the initiation of systemic corticosteroids and/or (2) an ER visit and/or hospital admission. |
At month 12
|
|
Percentage of Participants Achieving OCS Sparing Remission
Tidsramme: At month 12
|
OCS sparing is defined as (a) No clinically significant asthma exacerbations during the period of interest (b) No OCS use for asthma at the time point of interest. |
At month 12
|
|
Percentage of Participants Achieving 3-Component Clinical Remission
Tidsramme: At month 12
|
3-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an ACT |
At month 12
|
|
Mean Change from Baseline in Mini-Asthma Quality of Life Questionnaire (AQLQ) Overall Score
Tidsramme: Baseline and at month 12
|
The mini-AQLQ overall score is a reduced version of the AQLQ which includes 15 items. The minimally clinically important difference (MCID) is 0.5. The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability |
Baseline and at month 12
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 219871
- 2023 (U.S. NIH-bevilling/kontrakt)
- 2023-509026-21-00 (Registry Identifier: CTIS (EU))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD-delingsadgangskriterier
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .